Table 2.
Patients With HCV RNA Levels Below the Level of Quantification at Various Times of Treatment and Follow-upa
| Antiretroviral Therapy, No. (%) [95% CI]b |
||
|---|---|---|
| Week | No (n = 13) | Yes (n = 37) |
| Treatment Period | ||
| 4 | 13 (100) [75–100] | 37 (100) [91–100] |
| 8 | 13 (100) [75–100] | 37 (100) [91–100] |
| 12 | 13 (100) [75–100] | 37 (100) [91–100] |
| Postttreatment Period | ||
| 2 | 13 (100) [75–100] | 37 (100) [91–100] |
| 4 | 13 (100) [75–100] | 36 (97) [89–100] |
| 8 | 13 (100) [75–100] | 36 (97) [89–100] |
| 12 (SVR12) | 13 (100) [75–100] | 36 (97) [89–100] |
Abbreviation: SVR, sustained viral response.
a
Treatment response in all participants was included in the intention-to-treat analysis in all 50 participants. The RNA assay was used for these points, with a lower limit of quantification of 43 IU/mL.
b
The CI for proportion estimate for each treatment is obtained using the binomial distribution